Skip to main content
Premium Trial:

Request an Annual Quote

GlaxoSmithKline Will Use Beyond Genomics Platform

NEW YORK, Dec. 10-GlaxoSmithKline will use Beyond Genomics' systems biology platform to describe disease pathways and identify disease and drug response markers, the company said in a statement today.


The deal is an "evaluation agreement." Financial details and specifics of the agreement were not revealed.


Beyond Genomics, based in Waltham, Mass., combines proteomic and metabolomic analysis with pattern recognition and data mining software for a systems approach to drug discovery and development.


For further details, see the press release

The Scan

Science Confidence Boost

The New York Times reports that a new poll finds trust in science and scientists has increased with the COVID-19 pandemic.

Appeal and Funds

Some grant applications denied funding due to an Australian Research Council rule change have now been funded following an appeal, the Guardian reports.

Surveillance for Variants

Vox writes that the detection of the Omicron SARS-CoV-2 variant highlights the need for improved viral genomic surveillance.

Nature Papers Examine Taxonomic Gaps in Plant Sequencing, SARS-CoV-2-Human Interactome

In Nature this week: plant genome sequencing dominated by affluent countries, and more.